Alteogen Inc
KOSDAQ:196170

Watchlist Manager
Alteogen Inc Logo
Alteogen Inc
KOSDAQ:196170
Watchlist
Price: 309 000 KRW 4.04%
Market Cap: 16.5T KRW
Have any thoughts about
Alteogen Inc?
Write Note

Gross Margin
Alteogen Inc

43.3%
Current
26%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
43.3%
=
Gross Profit
32.2B
/
Revenue
74.4B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
KR
Alteogen Inc
KOSDAQ:196170
16T KRW
43%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
320.1B USD
67%
US
Amgen Inc
NASDAQ:AMGN
150.5B USD
60%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
86%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
78%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
135.4B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.9B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
34.5B EUR
89%
Country KR
Market Cap 16T KRW
Gross Margin
43%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 320.1B USD
Gross Margin
67%
Country US
Market Cap 150.5B USD
Gross Margin
60%
Country US
Market Cap 120.4B USD
Gross Margin
86%
Country US
Market Cap 113.8B USD
Gross Margin
78%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.4B AUD
Gross Margin
52%
Country US
Market Cap 82.9B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 34.5B EUR
Gross Margin
89%
No Stocks Found

Alteogen Inc
Glance View

Market Cap
16.4T KRW
Industry
Biotechnology

Alteogen Inc. is a biopharmaceutical company based in South Korea that has carved out a niche in the development of innovative drug delivery systems. Founded in 2005, the company specializes in the creation of biosimilars and biobetters – biologic drugs that improve upon existing therapies. With a strong pipeline aimed at addressing critical unmet medical needs, Alteogen focuses on therapeutic areas such as oncology, autoimmune diseases, and chronic conditions. One of their standout innovations is the proprietary technology for enhanced antibody-drug conjugates, which can significantly improve the efficacy and safety profiles of existing treatments. As the global demand for advanced therapeutics continues to rise, Alteogen presents a compelling story of potential growth driven by scientific innovation. For investors, Alteogen’s strategic partnerships and collaboration with major pharmaceutical companies amplify its growth trajectory. The company is not only positioned to benefit from its proprietary technologies but is also shaping its portfolio to align with the growing market for biosimilars. As competition in the biopharmaceutical space intensifies, Alteogen’s commitment to research and development sets it apart, showcasing its dedication to delivering next-generation medicines. With a robust clinical development pipeline and strong market momentum, Alteogen Inc. represents an intriguing opportunity for investors looking to tap into the evolution of healthcare and the future of targeted therapies.

Intrinsic Value
33 513.79 KRW
Overvaluation 89%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
43.3%
=
Gross Profit
32.2B
/
Revenue
74.4B
What is the Gross Margin of Alteogen Inc?

Based on Alteogen Inc's most recent financial statements, the company has Gross Margin of 43.3%.